share_log

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Fitzgerald Thomas A

Transcode Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Fitzgerald Thomas A

Transcode Therapeutics | 4：持股變動聲明-高管 Fitzgerald Thomas A
美股sec公告 ·  06/19 04:22
牛牛AI助理已提取核心訊息
Interim CEO and CFO of Transcode Therapeutics, Inc., Fitzgerald Thomas A, has engaged in a transaction involving the company's stock, as reported on June 14, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Fitzgerald Thomas A, which could be of interest to investors of Transcode Therapeutics, Inc. [RNAZ].
Interim CEO and CFO of Transcode Therapeutics, Inc., Fitzgerald Thomas A, has engaged in a transaction involving the company's stock, as reported on June 14, 2024. The specific details of the transaction, including the number of shares, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The action reflects a change in the holdings of Fitzgerald Thomas A, which could be of interest to investors of Transcode Therapeutics, Inc. [RNAZ].
2024年6月14日，Transcode Therapeutics，Inc.的臨時首席執行官和首席財務官Fitzgerald Thomas A參與了一項涉及該公司股票的交易。 公告中未披露交易的具體細節，包括股數，股票性質，成交價格和股票總價值。此舉反映了Fitzgerald Thomas A的持股變動情況，可能引起Transcode Therapeutics，Inc. [RNAZ]的投資者的關注。
2024年6月14日，Transcode Therapeutics，Inc.的臨時首席執行官和首席財務官Fitzgerald Thomas A參與了一項涉及該公司股票的交易。 公告中未披露交易的具體細節，包括股數，股票性質，成交價格和股票總價值。此舉反映了Fitzgerald Thomas A的持股變動情況，可能引起Transcode Therapeutics，Inc. [RNAZ]的投資者的關注。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。